Примери за използване на Must be advised на Английски и техните преводи на Български
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Ecclesiastic
-
Computer
Patients must be advised that they may experience neurologic events.
Women of childbearing potential Women of childbearing potential must be advised not to get pregnant during therapy.
Patients must be advised to cover the patch application site, e.g.
Women of childbearing potential Women of childbearing potential must be advised to use effective contraception during treatment.
Patients must be advised to report worsening signs and symptoms of asthma during therapeutic use to their physician.
Women of childbearing potential must be advised not to get pregnant during therapy.
Patients must be advised to notify their physician if they become pregnant or intend to become pregnant during treatment with aripiprazole.
Women of childbearing potential must be advised to avoid pregnancy while on Reagila.
Patients must be advised to exercise caution while driving or operating machines during treatment with naltrexone/bupropion, especially at the beginning of the treatment or during the titration phase.
Women of childbearing potential must be advised to avoid pregnancy while on Tarceva.
Patients must be advised to cover the transdermal patch application site, e.g. with clothing, if there is a risk of exposure to sunlight throughout the period of wear and for 10 days following its removal.
Women of childbearing potential must be advised to avoid pregnancy while on Tarceva.
Men must be advised to practice barrier contraception during treatment, and for at least 90 days thereafter, unless it is certain that the female partner is not at risk of pregnancy(see sections 4.6, 4.8 and 5.3).
Women of childbearing potential must be advised to avoid pregnancy while on Alecensa.
Patients must be advised that they may not feel the spray being administered, and that they should, therefore, rely on the audible click and the number on the counter advancing to confirm that a spray has been delivered.
When booking the car,our Contact Centre must be advised of any endorsements/ points on a driving licence;
Male patients must be advised to practice barrier contraception during and for at least 90 days following treatment with ganciclovir unless it is certain that the female partner is not at risk of pregnancy(see sections 4.4 and 5.3).
If pregnancy does occur during treatment orwithin four months from stopping treatment, the patient must be advised of the significant teratogenic risk of ribavirin to the foetus.
Women of childbearing potential must be advised to avoid pregnancy due to the clastogenic and teratogenic properties of the medicinal product.
Due to the unknown risk related to potential exposure during early pregnancy,women of childbearing potential must be advised not to become pregnant while using TORISEL.
Women of childbearing potential must be advised to use effective contraception during treatment.
Ziconotide may cause confusion, somnolence andother neurological adverse reactions, therefore patients must be advised not to drive or operate machines if affected.
Women of childbearing potential must be advised to use effective contraception during treatment with Tasigna.
However, given that some patients may experience drowsiness or difficulty with concentration, particularly early in treatment or after a dose increase,patients must be advised to exercise caution during activities requiring a high degree of alertness, e.g..
Therefore, women of child bearing potential must be advised to use effective contraception during treatment and for at least 30 days thereafter.
If pregnancy does occur during treatment orwithin four months from stopping treatment, the patient must be advised of the significant teratogenic risk of Rebetol to the foetus(see section 4.4).
Therefore men under therapy must be advised not to father a child and to use contraceptive measures during and at least 6 months after therapy.
If a pregnancy is diagnosed or planned,the treatment should be carefully reconsidered and the patient must be advised of the possible teratogenic risk of cysteamine(see section 4.6).
Women receiving ambrisentan must be advised of the risk of foetal harm and alternative therapy initiated if pregnancy occurs(see sections 4.3, 4.4 and 5.3).
As a result of the potential for reproductive toxicity and teratogenicity,women of childbearing potential must be advised to use effective contraception during and for at least 30 days after treatment.